# Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

> **NCT04826679** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 53 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Camrelizumab, nab-paclitaxel, cisplatin

## Key facts

- **NCT ID:** NCT04826679
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-04-01
- **Final completion:** 2026-04-01
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2021-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826679, "Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04826679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*